SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coca-Cola Company (The). The Group's principal activities are manufacturing, distributing and marketing nonalcoholic beverage concentrates and syrups. The products of the Group include carbonated soft drinks and also various kinds of non carbonated beverages. The Group sells these beverages, concentrates and syrups to bottling and canning operations, distributors, fountain wholesalers and retailers. The other products marketed and distributed by the Group include juice drinks, sports drinks, water products, teas, coffees and other beverage products. The Group also has ownership interests in various canning and bottling operations. The operations of the Group are conducted in the United States, Europe, Eurasia, Middle East, Africa, Latin America and Asia.

Coca-Cola Co

Coca-Colas stronger-than-expected Q2 results and raised full-year outlook, supported by resilient beverage demand and volume growth, have driven a sharp rally and fresh highs. Traders are largely celebrating the earnings momentum and defensive appeal, while others warn the stock looks overvalued or overbought after its run.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devons sale of its Eagle Ford assets to Crescent Energy for cash is drawing attention, with traders weighing the proceeds against the assets contribution to production and the companys broader portfolio streamlining. Some are puzzled that the shares are weak despite the sale, while others remain frustrated with DVNs relative performance.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Geopolitical supply concerns tied to the U.S.-Iran conflict, Strait of Hormuz shipping risks and attacks on regional energy infrastructure are keeping energy stocks in focus, alongside tight refined-fuel markets. Traders debate whether those risks will sustain support for XLE or whether diplomacy, recovering flows and profit-taking will unwind the risk premium; some also note the ETF has lagged crude at times.

StablecoinX, Inc. is an infrastructure software and services company. The firm is focusing on supporting the blockchain Ethena. The company was founded on July 7, 2025 and is headquartered in Frisco, TX.

StableCoinX Inc. - Ordinary Shares - Class A

Discussion centers on StablecoinXs large ENA treasury and traders view that USDE trades at a discount to its underlying asset value, making it a proxy for Ethena and broader crypto momentum. Optimism about ENA growth and a proposed buyback framework is tempered by concerns over warrant-related dilution, volatility, and repeated failed rallies.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnights mainnet launch and reported exchange availability are drawing attention, alongside validator and payment-network developments that supporters see as evidence of growing adoption. Traders remain divided, with some welcoming the projects privacy-focused progress while others cite unlock-related selling, weak price follow-through, and concerns about centralization.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Discussion centers on Phase 1 atopic dermatitis results for Corvuss oral ITK inhibitor soquelitinib, with bullish traders emphasizing reported skin-clearance and durability signals and its potential across indications. Others question the early-stage evidence and point to selling after the data, while short-interest and squeeze speculation add to the debate.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention after a sharp gold pullback and rebound, with traders debating whether the bounce marks a durable bottom or a temporary bull trap. The bullish case cites safe-haven demand, currency-debasement concerns and central-bank buying, while skeptics point to elevated Treasury yields, a firm dollar and expectations for higher rates.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is drawing attention amid a prolonged selloff in Chinese EV stocks, with traders focused on weak demand and profitability concerns and recent analyst downgrades. Bulls point to technology licensing, international expansion, autonomous driving and robotics as potential growth drivers, while skeptics question whether those initiatives can offset pressure in the core auto business.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirms strong quarterly results and upbeat outlook have fueled a volatile rebound, with traders watching a break above recent resistance. Bulls point to growth and analyst upgrades, while skeptics cite the sharp post-earnings selloff and macro risks, especially interest rates.

Zoracles

Sharp, intermittent rallies and volume spikes are driving attention, with traders speculating about a short squeeze while skeptics warn the moves may be pump-and-dump activity. Some also discuss Zoras expansion into attention markets, though they question whether the new product creates value for ZORA holders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did KPRX Stock Surge 17% Pre-Market Today?

Equity

The company announced a $24 million private placement, led by Perceptive Advisors and ADAR1 Capital Management.

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting...

Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know

Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Reported GAAP EPS of -$0.34 up 37.04% YoY

Kiora Pharmaceuticals continues to incur net losses while facing clinical trial execution risks and dependence on the successful completion of strategic transactions to secure additional capital for future operational needs.

Kiora Pharmaceuticals strengthened its financial position with a $24.0 million private placement, extending its operating runway into late 2028 while advancing clinical trials for KIO-301 with fully reimbursed development costs.

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Kiora Pharmaceuticals Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

KPRX Kiora Pharmaceuticals Inc

Fundamentals

Latest KPRX News